This is a multicenter, randomized, double-blind, placebo-controlled study evaluating
rosiglitazone: 4 mg tablets or placebo tablets administered orally twice daily for 12 weeks.
The purpose of the study is to evaluate the efficacy and safety of rosiglitazone in the
treatment of mild to moderately active ulcerative colitis. Disease activity will be measured
using a standard disease activity index. Calculation of the index requires patients to
undergo flexible sigmoidoscopy at the start of the study and at week 12.
Phase:
Phase 2
Details
Lead Sponsor:
James Lewis
Collaborators:
GlaxoSmithKline National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)